



Attorney's Docket No.: 00786-400002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

Applicant: Seth P. Finklestein

Art Unit : Unknown

FEB 2 8 2002

Filed

Title

Serial No.: 09/762,432 : August 7, 1998

Examiner: Unknown

**TECH CENTER 1600/2900** 

TREATMENT OF CENTRAL NERVOUS SYSTEM ISCHEMIA OR TRAUMA

WITH EPIDERMAL GROWTH FACTOR-LIKE POLYPEPTIDES

Commissioner for Patents Washington, D.C. 20231

## RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office action mailed November 15, 2001, Applicant elects the invention of Group I (claims 1-18), drawn to a method for reducing a neurological deficit. The Office action also requires election of a single species, the species being the "[d]ifferent EGFlike polypeptides (claims 6, 7, 8, 9, 20, 21 and 22)" (Office Action at page 3). In response, Applicant elects the species "epidermal growth factor," which reads on claims 1-6 and 14-18. The election is made without traverse.

No fees are believed due in connection with this response. If there are any fees, or any credits, please apply them to Deposit Account No. 06-1050.

Respectfully submitted,

Date: / Number 17 2001

Crews, Ph.D., Reg. No. 43,567

Fish & Richardson P.C. 225 Franklin Street

Boston, Massachusetts 02110-2804

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20360941.doc

## CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Dep

Signature

Typed or Printed Name of Person Signing Certificate